As a partner in the Intellectual Property practice group, Jeff concentrates on patent litigation and strategic counseling across a broad range of industries, including pharmaceutical, chemical, biotechnology, electrical engineering, agricultural, and food products. A registered patent attorney with over four decades of experience, Jeff has successfully represented both patent owners and challengers through every stage of federal litigation and appeals.
A significant portion of Jeff’s practice involves advising pharmaceutical clients on preinitiation evaluation of product candidates and developing patent challenge and defense strategies. Since the passage of the Hatch-Waxman Act, he has handled all aspects of pharmaceutical patent infringement cases, litigating disputes in federal courts nationwide and before the International Trade Commission. Jeff has served as lead counsel in both bench and jury trials and has extensive experience managing patent appeals, including arguments before the U.S. Court of Appeals for the Federal Circuit.
Clients rely on Jeff as a trusted advisor who delivers proactive, strategic counsel at the intersection of science and law. By aligning legal strategies with business priorities and understanding the perspective of in-house teams, he provides actionable insights that enable management to make informed, confident decisions.
In addition to litigation, Jeff offers strategic patent counseling, including advice on patent prosecution relating to drug substances and products, as well as products and methods for other technologies. He drafts invalidity, freedom-to-operate, and non-infringement opinions for pharmaceutical products and processes, and for other technologies, such as medical devices and food products.
Jeff is also highly experienced in Orange Book certification and listing strategies and represents pharmaceutical companies and their partners in 505(b)(2) and ANDA submissions for a wide range of products. He also has significant experience in trade secret matters, including those involving pharmaceutical products and processes, and has served as lead counsel in cases brought under the Defend Trade Secrets Act.
